Oops! It appears that you have disabled your Javascript. In order for you to see this page as it is meant to appear, we ask that you please re-enable your Javascript!

Myelodysplastic syndromes (MDS) are a group of hematopoietic progenitor cells clonal disorders due to a peripheral ineffective hematopoiesis characterized by periferical cytopenia, hypercellular bone marrow and an increased risk of progressing to acute myeloid leukemia (AML). MDS may be accompanied by an increase in blasts, less than 30%, and usually cytopenia of one or more cell lines. The myelodysplastic syndromes (MDS) may be primary (de novo) or secondary. Chromosomal abnormalities are present in 30-50% of primary myelodysplastic syndromes and 80% of secondary MDS. Myelodysplastic syndromes with complex karyotype (30%) are associated with further evolution to acute myeloid leukemia (AML).

5q31, EGR1 7q31, D7S486 Chr. 8 Chr. Y 20q12, D20S108 inv16, CBFB/MYH11